The introduction of long-acting b-agonist (LABA) drugs in the 1990s was considered a major
advance in bronchodilator therapy with evidence that their use led to improved lung function …

Asthma is a worldwide chronic disorder that is characterised by airway inflammation and
hyper-responsiveness, which results in intermittent airflow obstruction and subsequent …

Several studies suggested an association between the regular use of β 2-agonists and
asthma deaths. Whether this association represents adverse effects of β-agonist use or is …

Asthma ranks among the most common of chronic diseases in the Western world. Although
modern therapy has improved patient care, asthma still affects 5–10% of the population and …

The long-acting b-agonists (LABAs) were introduced as asthma treatments in the 1990s, and
their use was shown to result in improved lung function and quality of life. Concerns about …

Background The safe and appropriate use of long-acting beta-agonists (LABAs) for the
treatment of asthma has been widely debated. In two large clinical trials, investigators found …

Background: There is concern that long-acting β agonist (LABA) drugs may increase the risk
of asthma mortality. Methods: A meta-analysis was conducted of asthma deaths in …

Two very large, randomized, double-blind clinical trials performed in the United Kingdom
and in the United States have suggested that addition of salmeteräÊ to usual asthma …

The safety of long-acting β2-agonist (LABA) treatment in asthma has been questioned
following reported increased respiratory deaths when salmeterol was added to usual …

Reason for posting: A large, placebo-controlled trial of Serevent (salmeterol), a long-acting β
2-receptor agonist (LABA), was recently stopped early amid concerns that the drug may be …